

# Human chorionic gonadotropin and growth factors at the embryonic–endometrial interface control leukemia inhibitory factor (LIF) and interleukin 6 (IL-6) secretion by human endometrial epithelium

S.Perrier d’Hauterive<sup>1,2,5</sup>, C.Charlet-Renard<sup>1</sup>, S.Berndt<sup>3</sup>, M.Dubois<sup>2</sup>, C.Munaut<sup>3</sup>, F.Goffin<sup>2,3</sup>, M.-T.Hagelstein<sup>1</sup>, A.Noël<sup>3</sup>, A.Hazout<sup>4</sup>, J.-M.Foidart<sup>2,3</sup> and V.Geenen<sup>1</sup>

<sup>1</sup>Center of Immunology and <sup>3</sup>Laboratory of Tumour and Developmental Biology, Institute of Pathology CHU-B23 and <sup>2</sup>Department of Gynaecology and Obstetrics, University of Liege, B-4000 Liege-Sart Tilman, Belgium and <sup>4</sup>Bichat Hospital, Center of Reproductive Medicine, F-75006 Paris, France

<sup>5</sup>To whom correspondence should be addressed at: Center of Immunology, Institute of Pathology CHU-B23, University of Liege, B-4000 Liege-Sart Tilman, Belgium. E-mail: sperrier@ulg.ac.be

**BACKGROUND:** The elucidation of the molecular mechanisms by which the embryo contributes to its implantation is an area of extensive research. The main objective of this study was to investigate the pattern of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) secretion by human endometrial epithelium, and their regulation by human chorionic gonadotropin (hCG) and other growth factors present at the embryonic–endometrial interface. **METHODS:** Endometrial epithelial cells (EEC) were isolated from biopsies collected at both proliferative and secretory phases of fertile women. **RESULTS:** HCG (1–50 IU/ml) increased LIF secretion by EEC cultures derived from follicular phase (up to  $285 \pm 75\%$ ) or from secretory phase (up to  $212 \pm 16\%$ ). In contrast, hCG reduced IL-6 secretion by EEC in both phases. The hCG/LH receptor gene was transcribed by EEC as evidenced by RT–PCR. Insulin-like growth factors 1 and 2 increased LIF secretion by EEC. Transforming growth factor  $\beta$ 1 stimulated LIF and reduced IL-6 secretion. **CONCLUSIONS:** Through hCG, the blastocyst may be involved in the control of its implantation (via an increase of proimplantatory LIF) and tolerance (via an inhibition of proinflammatory IL-6). Other growth factors present at the embryonic–endometrial interface are also involved in the control of LIF and IL-6 endometrial secretion.

*Key words:* endometrium/human chorionic gonadotropin/insulin-like growth factors/interleukin 6/leukemia inhibitory factor/transforming growth factor beta

## Introduction

Implantation of the embryo into the uterine endometrium is a crucial step in the mammalian reproductive process and in the initiation of pregnancy. The success of implantation depends on a cross-talk that is both temporally and spatially synchronized between the blastocyst trophoblast and the endometrial epithelium. An appropriate apposition and close contact between trophoblastic cells and endometrial epithelial cells (EEC) is required for further embryonic development (Giudice, 1999). Human chorionic gonadotropin (hCG) is a specific embryonic glycoprotein, the gene of which (*HCG*) is transcribed as early as the 2-cell stage embryo (Jurisicova *et al.*, 1999). At the blastocyst stage, *HCG* transcripts are detected in trophoblastic cells of the human blastocyst, and hCG production can be detected on day 7 in blastocyst cultures (Dokras *et al.*, 1991; Lopata *et al.*, 1997). Significant levels of hCG may be measured in maternal blood on day 10

after ovulation, close to the time of implantation. In addition to its classical endocrine role as a luteotropic hormone responsible for the maintenance of progesterone production by the maternal corpus luteum, a series of seminal studies have shown that hCG exerts paracrine actions in the uterine environment (Fazleabas *et al.*, 1999; Rao, 2001, 2002). Those studies followed the discovery that receptors for hCG/luteinizing hormone (hCG/LHR) may be labelled by specific antibodies in the human uterus (Reshef *et al.*, 1990). Since then, the expression of hCG/LHR by the human endometrium has been further confirmed through hCG/LHR cDNA studies, radio-binding assays, western blotting, and covalent receptor cross-linking. Treatment of human endometrial glandular epithelial cells with hCG increases the expression of the cyclooxygenase-2 gene (*COX2*) (Zhou *et al.*, 1999). When hCG is introduced into the uterine cavity by microdialysis, levels of leukemia inhibitory factor (LIF),

vascular endothelial growth factor (VEGF) and metalloprotease 9 (MMP-9) increase in the uterine fluid, while insulin-like growth factor binding protein 1 (IGFBP-1) and monocyte colony-stimulating factor (M-CSF) levels decrease (Licht *et al.*, 2001). In addition, hCG induces morphological and functional differentiation of the endometrial stroma into decidua (Han *et al.*, 1999).

Different cytokines participate in the success of implantation and contribute to endometrial receptivity. Targeted inactivation of *Lif* in mice leads to a complete failure of blastocyst implantation that is rescued after intraperitoneal LIF administration (Stewart *et al.*, 1992). The role of LIF in human implantation is much less well established. The LIF protein and *LIF* messenger RNA are present in the human endometrium with a maximum level during the implantation window in EEC. At the same time, LIF receptor is expressed by the blastocyst and human endometrium (Charnock-Jones *et al.*, 1994; Arici *et al.*, 1995; Cullinan *et al.*, 1996; Laird *et al.*, 1997). Endometrial cells produce LIF *in vitro* but also *in vivo*. Delage *et al.* (1995a) demonstrated that the *in vitro* secretion by cultured endometrial explants obtained from infertile women were significantly lower when compared to fertile women. Laird *et al.* (1997) further confirmed that the amount of LIF in flushings obtained from women with unexplained infertility was significantly lower than those from normal fertile women on day LH + 10. On the contrary, when measured on day 26 of the cycle, a low concentration of LIF in uterine flushing is predictive of subsequent implantation. An excess of LIF in the luminal fluid at this time could reflect local inflammation which is detrimental for implantation (Ledee-Bataille *et al.*, 2002). Interleukin 6 (IL-6) is also secreted in the human endometrium following a temporal profile during the menstrual cycle, with levels rising during the luteal phase and menstruation (Tabibzadeh *et al.*, 1995; Vandermolen and Gu, 1996). The IL-6 receptor is expressed at the surface of the embryo, the trophoblast and the endometrium (Sharkey *et al.*, 1995). Blastocyst implantation is not impaired in *Il6*<sup>-/-</sup> mice, although the development of the conceptus is compromised (Robertson *et al.*, 1992; Kopf *et al.*, 1994; Salamonsen *et al.*, 2000).

The main objective of this study was to further explore the hypothesis that hCG, and growth factors present at the embryonic–endometrial interface and known to intervene in embryo development (IGFs and TGF- $\beta$ 1), are able to control LIF and IL-6 secretion by human EEC.

## Materials and methods

### Patients

Endometrial biopsies were collected from fertile women (one previous delivery) with normal cycles ( $n = 28$ ) undergoing surgery for voluntary sterilization or during hysteroscopy before assisted medical procreation (AMP) because of male infertility. The stage of the menstrual cycle was established from women's menstrual history (based on the first day of the last menstruation) and from histological dating performed by experienced pathologists, according to the criteria of Noyes *et al.* (1950). Fourteen patients were in the proliferative phase (group A) and fourteen in the secretory phase (group B). The mean age of group A was 33.5 years (range 18–45 years)

and the mean age of group B was 35 years (range 26–46 years). None of the patients received any hormonal treatment for 3 months prior to biopsy. The ethics committee of Liege Medical School approved the protocol, and informed consent was obtained from the patients.

### Separation of endometrial epithelial cells from stromal cells

Endometrial biopsy samples were collected in Hanks' balanced salt solution (HBBS) containing penicillin (100 IU/ml) and streptomycin (100  $\mu$ g/ml) and endometrial epithelial cells (EEC) were isolated following the method described by Laird *et al.* (1993). The tissues were finely chopped with scissors and digested for 45 min at 37°C in 5 ml of Dulbecco's modified Eagle's medium (DMEM) containing 0.2% collagenase type 1a (Sigma Aldrich, St Louis, MO). During incubation and at the end of incubation, the tissue was gently pipetted every 15 min to disperse the cells. The EEC were separated from stromal cells by centrifugation for 20 min at 100 g. Pellets contained mainly epithelial cells present both as small clumps and as separated cells. The two withdrawn supernatants, containing mainly stromal cells, were pooled and centrifuged at 300 g to pellet the cells. Epithelial and stromal cells were purified by unit density sedimentation. Each fraction of cells was resuspended in 2 ml DMEM containing 10% fetal calf serum (FCS), 1% glutamine and antibiotics, and gently pipetted onto 8 ml of DMEM + 10% FCS in a test tube and left for 30 min at room temperature. Afterwards, epithelial cells were in the lower 2 ml, while stromal cells were in the upper 8 ml of supernatants. Epithelial cells were used for immunocytochemistry, cell culture/cytokine production and for molecular biology. Before culturing in serum-free medium, epithelial cells were centrifuged at 100 g, and the pellets were washed three times with DMEM containing 1% glutamine, antibiotics, 0.3% bovine serum albumin and 25 mIU/ml human insulin. Stromal cells were used only for immunocytochemistry.

### Cell cultures

EEC were plated into 24-well plates at  $2 \times 10^5$  cells per ml and per well and cultured for 72 h in DMEM with 1% glutamine, 0.3% bovine serum albumin and 25 mIU/ml human insulin. Each treatment was applied in a micro volume (50  $\mu$ l) at the beginning of incubation. Each condition was tested in triplicate. Too few EEC after separation resulted in the exclusion of the explant from some treatments. The cells used for immunocytochemistry were cultured for 24 h on multi-test slides in media containing DMEM with 1% glutamine, 25 mIU/ml human insulin and 10% FCS.

### Cytokines, growth factors and antibodies

Recombinant (rec) IL-1 $\beta$  was provided by Preprotech (London, UK) and used at a final concentration range between  $10^{-9}$  and  $10^{-12}$  M. Rec IL-1 $\alpha$  was obtained from Genzyme (Cambridge, UK) and was used at  $10^{-9}$  M. Anti-human IL-1 $\beta$  antibody was provided by R&D Systems (Abingdon, UK) and used at a concentration of 50  $\mu$ g/ml. Phytohemagglutinin (PHA) was provided by Glaxo-Wellcome (Zebulon, USA) and used at a final concentration of 5  $\mu$ g/ml. Lipopolysaccharide (LPS) was purchased from Sigma and used at a final concentration of 20  $\mu$ g/ml. Human chorionic gonadotropin (hCG) (Pregnyl) was provided by Organon (Brussels, Belgium) and was added at a final concentration of 1, 5, 10 and 50 IU/ml. Anti-hCG antibody from Santa Cruz Biotechnology (Santa Cruz, USA) was added at a final concentration of 2  $\mu$ g/ml. Transforming growth factor- $\beta$ 1 (TGF- $\beta$ 1) was prepared according to the methodology of Cone *et al.* (1988) and used at  $10^{-8}$ ,  $10^{-10}$  and  $10^{-12}$  M. Human insulin-like growth factor (IGF)-1 and IGF-2 (R&D Systems) were used at three final concentrations:  $10^{-8}$ ,  $10^{-10}$  and  $10^{-12}$  M.

Anti-human cytokeratin (5, 6, 8, 17 and 19) mAb (clone MNF 116, code no. M0821) and anti-vimentin V9 were from Dako (Copenhagen, Denmark). mAb anti-CD45RB was obtained from Dako. Second antibodies (Jackson, Pennsylvania, USA) were fluorescein (FITC)-conjugated goat anti-mouse IgG (second antibody A) and rhodamine (TRITC)-conjugated goat anti-rabbit IgG (second antibody B).

#### Cytokine immunoassays

Supernatants of cultured EEC were collected for assay after 72 h. Collected media were stored at  $-20^{\circ}\text{C}$  until cytokine measurements. All cytokine (IL-6 and LIF) concentrations were measured with specific ELISAs (Biosource-Europe, Nivelles, Belgium) according to appropriate instructions (De Groote *et al.*, 1992). Sensitivity was 20 pg/ml for LIF and 3 pg/ml for IL-6. Range was 150–8200 pg/ml for LIF and 8.5–540 pg/ml for IL-6. Inter and intra-assay coefficients of variation (CV) for LIF were  $<8.4\%$  and  $<5\%$ , respectively. Inter and intra-assay CV for IL-6 were  $<9.3\%$  and  $<7.7\%$ . For LIF assays, results obtained were usually in the standard curve and a preliminary dilution was not necessary. When some rare results were not in the standard curve, a new assay was performed with diluted supernatants. For IL-6 assay, the supernatants were usually diluted (systematically for the IL-1 $\beta$  condition) to ensure that they were in the limits of the standard curve.

#### Proliferation test

Proliferation tests were performed on EEC cultured for 72 h from three different endometria, using a 5-bromo-2'-deoxyuridine (BrdU) cell proliferation colorimetric immunoassay provided by Roche, according to the manufacturer's instructions.

#### Immunocytochemistry

Multitest slides were kept for 24 h in FCS–epithelial or stromal cell medium to allow cell plating (5000 cells/well) and then stained after  $-20^{\circ}\text{C}$  methanol fixation (Robert *et al.*, 1991; Martens *et al.*, 1996). Slides were first incubated with 10% normal goat serum to prevent non-specific binding of goat second antibody to mouse or rabbit Ig. Immunostaining was performed with the following reagents: anti-human cytokeratin mAb MNF 116 diluted at 1:50, anti-vimentin V9 mAb diluted at 1:500, or anti-CD45RB mAb diluted at 1:100, followed by second antibody A or B. The slides were mounted with glycerol/gelatin medium and observed using an Olympus fluorescence microscope. Images were collected with 20 $\times$  and 40 $\times$  objectives. A mercury source was used for fluorescein (488 nm) and rhodamine (568 nm).

#### Molecular biology

##### RNA extraction

EEC samples isolated from seven different endometrial biopsies were frozen in liquid nitrogen (or at  $-70^{\circ}\text{C}$ ). Total RNA was extracted using an RNeasy Mini Kit<sup>®</sup> from Qiagen (Valencia, USA) according to the manufacturer's instructions. Samples were treated by RNase free DNase (Roche, Indianapolis, USA) to remove potentially contaminating DNA. The integrity of extracted RNA was assessed by electrophoresis in ethidium bromide-stained 1% agarose MOPS/EDTA gel.


##### RT-PCR

Two hundred and fifty nanograms of total RNA were subjected to reverse-transcriptase using First Strand cDNA Synthesis Kit (Roche). In this method, RNA is reverse transcribed by AMV into single-stranded cDNA. The cDNA was secondarily amplified by

FastStart Taq DNA Polymerase (Roche) using the primers corresponding to human hCG/LHR cDNA sequence (upper primer 5'-GGCCGAAAACCTTGGATATTT-3', position 676–696; and lower primer 5'-GTAAGTCAACGTGGCCTCCAG-3', position 813–833). The expected PCR product was 158 bp in length. Human  $\beta$ -actin PCR primer pair (R&D Systems, Abingdon, UK) was used, resulting in a PCR product of 528 bp. Fifty microlitres of PCR reaction mixture contained 20 pmol of each oligonucleotide primer and 2 IU of Taq DNA polymerase. The reaction was started at  $94^{\circ}\text{C}$  for 5 min and run for 40 cycles (45 sec at  $94^{\circ}\text{C}$ , 45 sec at  $61^{\circ}\text{C}$  and 1 min at  $72^{\circ}\text{C}$ ). Aliquots of 15  $\mu\text{l}$  of amplified fragments were visualized in ethidium bromide-stained 2% agarose gel. The size of DNA species generated was determined using EZ load precision Molecular Mass Standard (Bio-Rad, Hercules, USA) and a 100 bp ladder (Pharmacia Biotech, Uppsala, Sweden). RT-PCR products were sequenced using ABI prism BigDye Terminator Cycle Sequencing Ready Reaction Kit protocol (Genomexpress, Meylan, France) to ensure hCG/LHR identity.

#### Mathematical and statistical analyses

Because of individual variability, all data have been normalized and expressed as the percentage of the mean of basal values (mean  $\pm$  SEM). For each experiment (except when specified), statistical analysis of the response to any kind of treatment was performed for the difference with basal value. The significance of differences was evaluated using unpaired nonparametric Mann–Whitney test with confidence intervals of 95%. Statistical analyses were performed using GraphPad Prism software.



**Figure 1.** (A) Immunostaining of the epithelial fraction of human endometrium with mAb anti-cytokeratin MNF 116, 1:50. (B) Immunostaining of the stromal fraction of human endometrium with mAb anti-vimentin V9, 1:500.



## Results

### Characterization of cell cultures

#### Immunocytochemistry

The epithelial nature of the cells pelleted after 100 g centrifugation was demonstrated by their intense staining with a mAb against human cytokeratin MNF 116 (Figure 1A). These cells were not stained either by a mAb against vimentin, or by a mAb staining all white blood cells (anti-CD45RB) (data not shown). Cytokeratin-positive epithelial cells represented >95% of the total cell population. By contrast, >95% of the cells in the supernatants were vimentin-positive and cytokeratin-negative stromal cells (Figure 1B). Results were similar without serum adduct, with restriction of lower cell adhesion (data not shown).


#### Cytokine production

Under basal conditions, cultured human EEC spontaneously secreted LIF and IL-6 (Table I). This production increased in a time-dependent way with a maximum level after 3 days of culture (data not shown). A 72 h incubation was therefore selected for all further experiments. The addition of LPS (20  $\mu\text{g/ml}$ ), PHA (5  $\mu\text{g/ml}$ ), or a combination of both did not induce any significant increase in cytokine secretion compared to the basal condition (Figure 2A).

The addition of a small amount of IL-1 $\beta$  ( $10^{-9}$  M) markedly increased LIF secretion. This stimulating effect of IL-1 $\beta$  was already observed at  $10^{-12}$  M and increased progressively from  $10^{-12}$  M to  $10^{-9}$  M (Figure 2B). A response of the same amplitude was observed with IL-1 $\alpha$  at  $10^{-9}$  M. IL-1 $\beta$

**Table I.** Mean of basal productions (pg/ml) of LIF and IL-6 by EEC from all proliferative and secretory endometria

	Phase	Basal production (pg/ml)	Standard error	<i>n</i>	Mann-Whitney test
LIF (pg/ml)	Proliferative	320.9	45.29	14	<i>P</i> = 0.7 (NS)
	Secretory	331.9	42.29	14	
IL-6 (pg/ml)	Proliferative	272.4	39.9	14	<i>P</i> = 0.07 (NS)
	Secretory	522.3	92.6	14	



**Figure 2.** (A) Production of LIF and IL-6 by 72h cultures of human EEC under basal conditions, and after treatment with PHA (phytohemagglutinin), LPS (lipopolysaccharide), the combination of both, and IL-1 $\beta$  ( $10^{-9}$  M). *n* = 3 (proliferative and secretory phases pooled). Results are expressed as mean  $\pm$  standard error of percentage of basal. \*\*\**P* < 0.001; NS = not significant by Mann-Whitney test. (B) Production of LIF and IL-6 by 72h cultures of human EEC under basal conditions, and after treatment with IL-1 $\beta$  ( $10^{-12}$  M to  $10^{-9}$  M) and IL-1 $\alpha$  ( $10^{-9}$  M). *n* = 4 (proliferative and secretory phases pooled). Results are expressed as mean  $\pm$  standard error of percentage of basal. \*\*\**P* < 0.0001; NS = not significant by Mann-Whitney test.

**Table II.** Absorbance values (mean  $\pm$  standard deviation) after BrdU proliferation test by ELISA

N = 3	Absorbance (mean $\pm$ St.dev.)	Mann-Whitney test
Basal	0.10 ( $\pm$ 0.02)	NS
hCG 50 IU/ml	0.10 ( $\pm$ 0.02)	NS
IGF1 $10^{-8}$ M	0.13 ( $\pm$ 0.05)	NS
IGF2 $10^{-8}$ M	0.13 ( $\pm$ 0.03)	NS
TGF- $\beta$ 1 $10^{-8}$ M	0.09 ( $\pm$ 0.06)	NS
IL-1 $\beta$ $10^{-9}$ M	0.14 ( $\pm$ 0.04)	NS
EGF	0.22 ( $\pm$ 0.07)	$P = 0.02$
FCS 10%	0.25 ( $\pm$ 0.05)	$P = 0.016$

Statistical analyses performed using Mann-Whitney test.  
NS = not significant.

also induced a strong concentration-dependent increase of endometrial IL-6 secretion (Figure 2B). Consequently, treatment with IL-1 $\beta$  ( $10^{-9}$  M) was used as positive control in all cultures.

### Regulation of endometrial cytokine production by hCG, IGFs and TGF- $\beta$ 1

Results were analysed according to the phase of the menstrual cycle: group A for proliferative phase and group B for secretory phase. The proliferative effect of the different reagents tested on EEC cultured for 72 h was assessed in triplicate by a BrdU cell proliferation test provided by Roche (Table II). No significant proliferative effect was found for hCG (50 IU/ml), IGF-1 ( $10^{-8}$  M), IGF-2 ( $10^{-8}$  M), TGF- $\beta$ 1 ( $10^{-8}$  M) or IL-1 $\beta$  ( $10^{-9}$  M).

#### Effect of hCG

In both groups, hCG at concentrations ranging between 1 and 50 IU/ml stimulated the secretion of LIF by EEC in a concentration-dependent manner after 72 h (Figure 3A). This stimulating effect of hCG (50 IU/ml) was inhibited by a neutralizing anti-hCG antibody (2  $\mu$ g/ml) (Figure 3C). This effect of hCG on LIF production was not mediated by IL-1 $\beta$  since a blocking antibody to IL-1 $\beta$  did not modify the response to hCG (Figure 3D). Interestingly, hCG exerted an opposite effect on IL-6, reducing its production in both groups (Figure 3B). This effect was also inhibited by the neutralizing anti-hCG antibody (2  $\mu$ g/ml) (Figure 3C). Statistical analyses did not reveal any significant difference in hCG effects between the two groups.

#### Effect of IGF-1 and IGF-2

IGF-1 (Figure 4A) and IGF-2 (Figure 4B) induced a concentration-dependent increase of LIF production by endometrial epithelial cells after 72 h, but did not exert any significant effect on IL-6 production. All EEC from both secretory and proliferative phases responded similarly to IGF-1 and IGF-2 with regard to LIF and IL-6 secretion.

#### Effect of TGF- $\beta$ 1

In both groups, TGF- $\beta$ 1 induced a concentration-dependent increase of LIF secretion, and a concentration-dependent decrease of IL-6 secretion (Figure 5). No significant difference was found between the two groups.


### Expression of human hCG/LHR in human endometrium

As shown in Figure 6, transcripts of the hCG/LHR gene were evidenced by RT-PCR analyses performed on EEC isolated from endometria either in proliferative or in secretory phase. These results have been repeated and confirmed on five other different EEC samples. Human granulosa cells were used as positive control. RT-PCR products were sequenced and were found to correspond with the *Homo sapiens* luteinizing hormone receptor (gi 4557716).


### Discussion

The epithelial nature of the pelleted endometrial cells was confirmed by their intense staining with a mAb against cyto-keratin, and by the absence of any staining with a mAb against vimentin as well. The absence of contaminating leukocytes was shown by the failure of any cell labelling by a mAb anti-CD45RB and was confirmed by the incapacity for LPS or PHA (or both) to modify LIF and IL-6 secretion by EEC. Human endometrial epithelium spontaneously secreted LIF and IL-6 in proliferative and in secretory phase. When the basal production of all the biopsies in proliferative phase or in the secretory phase were pooled, there were no statistically significant differences between proliferative phase and secretory phase. These results are not in contradiction with the *in vivo* profile of LIF (increased in late proliferative and early secretory phase) or IL-6 (increased in secretory phase) productions by EEC. Indeed, our results did not exclude that, for any patient, its basal production of LIF or IL-6 is higher in the secretory phase compared to the proliferative phase. Moreover, our results concerning LIF basal production are not inconsistent with those of Laird *et al.* (1997) since we did not subdivide the phases in early, mid and late proliferative/secretory phase as those authors did. The basal production of LIF and IL-6 follows a time-dependent pattern, the maximum being reached after 3 days of culture. Thus, a 72 h incubation was selected for all further experiments. IL-1 $\beta$   $10^{-9}$  M strongly stimulated both LIF and IL-6 secretion by human EEC and was used as positive control in further experiments. We further extend previous results obtained for LIF by Arici *et al.* (1995) on stromal cells and Delage *et al.* (1995b) and confirm the results obtained by Laird *et al.* (1994) and Vandermolen and Gu (1996) for IL-6. Since the degree of cytokine response significantly varied from one woman to another, all the cytokine data were normalized (see Materials and methods). None of the factors tested at the highest concentration could induce a proliferative effect as tested with a BrdU cell proliferation ELISA.

LIF is known to stimulate hCG production by trophoblast (Nishino *et al.*, 1990; Sawai *et al.*, 1995). In our cultures of human EEC, hCG stimulated LIF production in a concentration-dependent way, suggesting that the blastocyst may influence its own implantation through hCG. This positive effect of hCG on LIF production was specific since it was blocked by a neutralizing anti-hCG antibody and not mediated by a local action of IL-1 $\beta$  since it was not blocked by an anti-IL-1 $\beta$  antibody. Our results also confirm and add to the *in vivo* results of Licht *et al.* (2001) who observed an




**Figure 3.** (A) Production of LIF by EEC in proliferative phase ( $n = 9$ ) and secretory ( $n = 12$ ) phase under basal conditions and after treatment with hCG (1–50 IU/ml) expressed as mean  $\pm$  standard error of percentage of basal. The LIF response to IL-1 $\beta$  is shown as positive control. \* $P = 0.004$ , \*\* $P < 0.0001$ , NS = not significant by Mann–Whitney test. (B) Concentration-dependent effect of hCG (1–50 IU/ml) on IL-6 production by human EEC in proliferative phase ( $n = 9$ ) and in secretory phase ( $n = 12$ ). The IL-6 response to IL-1 $\beta$  is shown as positive control. Results are expressed as mean  $\pm$  standard error of percentage of basal. \* $P = 0.002$ ; \*\* $P = 0.0008$ ; \*\*\* $P < 0.0001$  by Mann–Whitney test. (C) Effect of hCG (50 IU/ml) on LIF and IL-6 production by human EEC. A neutralizing antibody against hCG (2  $\mu$ g/ml) inhibits the LIF and IL-6 responses to hCG (50 IU/ml).  $n = 6$  (proliferative and secretory phases pooled). Results are expressed as mean  $\pm$  standard error of percentage of basal. \*\* $P = 0.0004$ ; \*\*\* $P < 0.0001$ ; NS = not significant (vs basal);  $\blacklozenge P < 0.0001$ ,  $\blacklozenge\blacklozenge P = 0.0004$  (vs hCG 50 IU/ml) by Mann–Whitney test. (D) Concentration-dependent effect of hCG (5–50 IU/ml) on LIF production by human EEC. A blocking antibody against IL-1 $\beta$  (50  $\mu$ g/ml) does not modify the LIF response to hCG (50 IU/ml).  $n = 4$  (proliferative and secretory phases pooled). Results are expressed as mean  $\pm$  standard error of percentage of basal. \* $P = 0.002$ ; NS = not significant (vs basal); NS = not significant (vs hCG 50 IU/ml);  $\blacklozenge\blacklozenge\blacklozenge P = 0.002$  (vs IL-1 $\beta$  10<sup>-9</sup>M) by Mann–Whitney test.




**Figure 4.** (A) Effect of IGF-1 ( $10^{-12}$ M to  $10^{-8}$ M) on LIF and IL-6 production by 72 h cultures of human EEC in proliferative phase ( $n = 6$ ) and in secretory phase ( $n = 9$ ). Results are expressed as mean  $\pm$  standard error of percentage of basal. (B) Effect of IGF-2 ( $10^{-12}$ M to  $10^{-8}$ M) on LIF and IL-6 production by 72 h cultures of human EEC in proliferative phase ( $n = 6$ ) and in secretory phase ( $n = 9$ ). Results are expressed as mean  $\pm$  standard error of percentage of basal. \* $P = 0.02$ ; \*\* $P = 0.006$ ; \*\*\* $P = 0.0002$ ; \*\*\*\* $P < 0.0001$ ; NS = not significant by Mann–Whitney test.





**Figure 5.** Effect of TGF- $\beta$ 1 ( $10^{-12}$  M to  $10^{-8}$  M) on LIF and IL-6 production by 72 h cultures of human EEC in proliferative phase ( $n = 10$ ) and in secretory phase ( $n = 8$ ) expressed as mean  $\pm$  standard error of percentage of basal. The LIF and IL-6 responses to IL-1 $\beta$  are shown as positive control. \*\*\* $P < 0.0001$  by Mann-Whitney test.



**Figure 6.** Detection by RT-PCR of human *hCG/LHR* gene transcripts. Left: amplification of cDNA obtained with *hCG/LHR*-specific primers (158 bp). Right: amplification of cDNA obtained with  $\beta$ -actin specific primers as internal control (528 bp). MM: EZ load precision molecular mass standard. NC: H<sub>2</sub>O (negative control). C + = granulosa cells; E1=EEC from an endometrium in proliferative phase; E2=EEC from an endometrium in secretory phase.

increase of LIF levels in uterine fluids after microdialysis of the uterine cavity with hCG. The expression of *hCG/LHR* by human endometrial epithelium in proliferative and secretory phase was evidenced by RT-PCR. Some controversy about the classical *LH/hCGR* expression in the human endometrium was raised by Stewart *et al.* (1999) and Stewart (2001). Several groups have however shown the presence of *hCG/LHR* in extragonadal human, rabbit or mouse female reproductive organs (Ziecik *et al.*, 1986; Jensen and Odell, 1988; Bonnamy *et al.*, 1990; Reshef *et al.*, 1990; Bhattacharya *et al.*, 1993; Bonnamy *et al.*, 1993; Derecka *et al.*, 1995; Zhang *et al.*, 2001). Moreover, using nested RT-PCR, Licht *et al.* (2003) recently demonstrated the expression of full-length *hCG/LHR* mRNA in human endometrium regulated by alternative splicing. In our study, we detected *hCG/LHR* transcripts on EEC by non-nested RT-PCR assays. Despite not observing an

effect of cycle stage on the ability of hCG to regulate LIF and IL-6 in EEC cultures, the *hCG/LHR* expression seems to be lower in the proliferative phase compared to the secretory phase. Further Real Time RT-PCR experiments are necessary to exactly quantify the amount of *hCG/LHR* expression throughout the cycle. As suggested by Fazleabas *et al.* (1999) in the *Papio anubis* endometrium, our results confirm that hCG, besides its endocrine role in maintaining progesterone production by the corpus luteum, also exerts a paracrine action on the human endometrial epithelium.

Previous studies have shown that IL-6 interacts with IL-6 receptor on the trophoblast, resulting in hCG release (Nishino *et al.*, 1990; Masuhiro *et al.*, 1991; Li *et al.*, 1992). Our results show that hCG interacts with *hCG/LH-R* on EEC, resulting in IL-6 inhibition. Further experiments are necessary to elucidate whether hCG could also have such a negative



feed-back on IL-6 secretion by trophoblast. Through the inhibition of the pro-inflammatory endometrial IL-6, hCG may play a new role as an immune regulator at the embryonic–endometrial interface during implantation. In our cultures of purified EEC from 28 fertile women, we did not obtain the same results as Uzumcu *et al.* (1998) who used a mixed population of endometrial cells from six IVF patients, and who observed that hCG (100 and 500 IU/ml) stimulated IL-6 production. The role of hCG as immunosuppressive factor was already suggested by its inhibition of PHA- or concanavalin A-mediated proliferation of human lymphocytes *in vitro*. Moreover, hCG inhibits IL-2 and simultaneously stimulates sIL-2R (a soluble form of the IL-2R which modulates IL-2 bioavailability) secretion by cultures of human peripheral blood mononuclear cells, suggesting a direct role for hCG in regulation of lymphocyte biological activity (Nakayama *et al.*, 2002). Khan *et al.* (2001) also confirmed the regulatory role of hCG on Th1 cell activity since the treatment of non-obese diabetic (NOD) mice with hCG before the onset of clinical symptoms dramatically inhibited the development of diabetes for a prolonged period of time. Transfer of spleen cells from the hCG-treated NOD mice into immunodeficient NOD/SCID mice blocked the development of diabetes in these mice (Khan *et al.*, 2001). Finally, recent results of Kayisli *et al.* suggested that hCG could be a link in the development of maternal immunotolerance and may facilitate trophoblast invasion by regulating proapoptotic molecules such as Fas–Fas ligand system in endometrial cells (Kayisli *et al.*, 2003).

IGFs induced a marked increase of LIF secretion without any significant effect on IL-6. In the endometrium, IGFs and their binding proteins (IGFBPs 1–6) are derived from stromal cells, whereas the epithelium predominantly expresses IGF receptors (IGF type 1 receptor or IGF-1R, IGF type 2 receptor or M6P/IGF-2R) (Rutanen, 1998). IGFs and predominantly IGF-2 are also detected in many fetal tissues from the first trimester (Han and Carter, 2000). In mouse embryos, increasing *Igf1* mRNA levels are observed between the 8-cell and blastocyst stages (Doherty *et al.*, 1994), while *Igf2* expression has been detected from the 2-cell stage. In addition to a paracrine/autocrine control of the cycling endometrial development, the IGFs and their binding proteins appear to play a crucial role during implantation and establishment of pregnancy (Nayak and Giudice, 2003). It is increasingly evident that disturbances in the IGF system occur in complications of human pregnancy, such as intrauterine growth restriction, as well as pre-eclampsia (Irwin *et al.*, 1999). In our experimental model, we show that, in the presence of IGF-1 and IGF-2, pro-implantatory LIF production by EEC is increased *in vitro*. The *in vivo* source of IGF-1 and -2 might be endometrial stromal cells, but also the pre-implantatory embryo. Indeed, *IGF1* and *IGF2* mRNA are expressed by human trophoblast, IGF-2 being the most abundantly expressed.

The TGF- $\beta$ 1 isoform markedly enhanced LIF secretion while, like hCG, it reduced IL-6 release by cultured epithelial cells from the human endometrium. The TGF- $\beta$  superfamily related glycoproteins are well known for their role in the

induction of embryonic mesoderm and also for their immunosuppressive properties. In mammals, there are four isoforms of TGF- $\beta$ : TGF- $\beta$ 1, - $\beta$ 2, - $\beta$ 3 and - $\beta$ 4 (Tabibzadeh *et al.*, 1998). The TGF- $\beta$  superfamily involves many members, such as bone morphogenic proteins, inhibins, activins and Müllerian inhibitory factor. TGF- $\beta$  is known to induce *in vitro* cytotrophoblast differentiation into syncytiotrophoblast, controlling then the process of placentation. The four isoforms of TGF- $\beta$  are present in the endometrial epithelium and stroma throughout the menstrual cycle in a time-dependent manner, their expression being the highest in the secretory phase (Kauma *et al.*, 1990; Casslén *et al.*, 1998; Godkin and Doré, 1998; Tabibzadeh *et al.*, 1998). Our data show that, besides its mesoderm-inducing properties within the embryo, TGF- $\beta$ 1 may also contribute both to implantation by enhancing endometrial LIF production, and to maternal tolerance of the fetal graft by inhibiting IL-6 release. This tolerogenic action of the TGF- $\beta$  superfamily had already been suggested by expression of a TGF- $\beta$ 2-related molecule in the murine decidua (Clark *et al.*, 1995; Merali *et al.*, 1996). Our results are in line with Arici *et al.* (1995) who demonstrated that TGF- $\beta$  and IL-1 $\beta$  are potent inducers of LIF expression in endometrial stromal cell culture.

Although IL-6 and LIF signal through the same molecule gp 130, they may exert different effects in endometrial cells, suggesting the activation of different intracellular signalling pathways, which may ultimately be important in the control of endometrial function (Ernst and Jenkins, 2004). This was also suggested by Cork *et al.* (2001) on epithelial and stromal cells since LIF and IL-6 had no effect on tumour necrosis factor (TNF- $\alpha$ ) production, whereas IL-11, another member of the family, caused a decrease in TNF- $\alpha$  production (Cork *et al.*, 2001).

In conclusion, this study shows that hCG treatment of human EEC in culture increases LIF secretion and inhibits IL-6 secretion in a concentration-dependent manner. Other growth factors present at the embryonic–endometrial interface (IGFs and TGF- $\beta$ 1) also promote endometrial secretion of the pro-implantatory LIF, while TGF- $\beta$ 1 strongly inhibits endometrial production of the pro-inflammatory IL-6. These observations suggest that the human blastocyst may contribute both to its implantation through an increase of endometrial LIF secretion and to its tolerance through an inhibition of endometrial IL-6 production.

### Acknowledgements

Sophie Perrier d'Hauterive is Research Assistant and V. Geenen is Research Director at the National Fund of Scientific Research (NFSR) of Belgium. These studies were supported by the Fondation Léon Fredericq (Liège Medical School), NFSR and by the Fédération Belge contre le Cancer.

### References

- Arici A, Engin O, Attar E and Olive DL (1995) Modulation of leukemia inhibitory factor gene expression and protein biosynthesis in human endometrium. *J Clin Endocrinol Metab* 80,1908–1915.
- Bhattacharya S, Banerjee J, Sen S and Manna PR (1993) Human chorionic gonadotropin binding sites in the human endometrium. *Acta Endocrinol* 129,15–19.

- Bonnamy PJ, Benhaim A and Leymarie P (1990) Estrous cycle-related changes of high affinity luteinizing hormone/human chorionic gonadotropin binding sites in the rat uterus. *Endocrinol* 126,1264–1269.
- Bonnamy PJ, Benhaim A and Leymarie P (1993) Uterine luteinizing hormone/human chorionic gonadotropin-binding sites in the early pregnant rat uterus: evidence for total occupancy in the periimplantation period. *Endocrinol* 132,1240–1246.
- Casslén B, Sandberg T, Gustavsson B, Willén R and Nilbert M (1998) Transforming growth factor beta1 in the human endometrium. Cyclic variation, increased expression by estradiol and progesterone, and regulation of plasminogen activators and plasminogen activator inhibitor-1. *Biol Reprod* 58,1343–1350.
- Charnock-Jones DS, Sharkey AM, Fenwick P and Smith SK (1994) Leukemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the blastocyst contains mRNA for the receptor at this time. *J Reprod Fertil* 101,421–426.
- Clark DA, Flanders KC, Hirte H, Dasch JR, Coker R, McAnulty RJ and Laurent GJ (1995) Characterization of murine pregnancy decidua transforming growth factor beta. Transforming growth factor beta 2-like molecules of unusual molecular size released in bioactive form. *Biol Reprod* 52,1380–1388.
- Cone JL, Brown DR and DeLarco JE (1988) An improved method of purification of transforming growth factor, type beta from platelets. *Anal Biochem* 168,71–74.
- Cork BA, Li TC, Warren MA and Laird SM (2001) Interleukin-11 (IL-11) in human endometrium: expression throughout the menstrual cycle and the effects of cytokines on endometrial IL-11 production in vitro. *J Reprod Immunol* 50,3–17.
- Cullinan EB, Abbondanzo SJ, Anderson PS, Pollard JW, Lessey BA and Stewart CL (1996) Leukemia inhibitory factor (LIF) and LIF receptor expression in human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation. *Proc Natl Acad Sci USA* 93,3115–3120.
- De Groote D, Zangerle PF, Gevaert Y et al. (1992) Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. Comparison with isolated PBMC stimulation. *Cytokine* 4, 239–248.
- Delage G, Moreau JF, Taupin JL et al. (1995a) In-vitro endometrial secretion of human interleukin for DA cells/leukaemia inhibitory factor by explant cultures from fertile and infertile women. *Hum Reprod* 10,2483–2488.
- Delage G, Moreau JF, Taupin JL, Hambartsoumian E, Frydman R, Tartzkovsky B and Chaouat G (1995b) In vitro modulation of the production of the cytokine HILDA/LIF, secreted by human endometrial explants: preliminary results. *Contracept Fertil Sex* 23,622–625.
- Derecka K, Pietila EM, Rajaniemi HJ and Ziecik AJ (1995) Cycle dependent LH/hCG receptor gene expression in porcine nongonadal reproductive tissues. *J Physiol Pharmacol* 46,77–85.
- Doherty AS, Temeles GL and Schultz RM (1994) Temporal pattern of IGF-I expression during mouse preimplantation embryogenesis. *Mol Reprod Dev* 37,21–26.
- Dokras A, Sargent IL, Ross C, Gardner RL and Barlow DH (1991) The human blastocyst: morphology and human chorionic gonadotropin secretion in vitro. *Hum Reprod* 6,1143–1151.
- Ernst M and Jenkins BJ (2004) Acquiring signalling specificity from the cytokine receptor gp130. *Trends Genet* 20,23–32.
- Fazleabas AT, Donnelly KM, Srinivasan S, Fortman JD and Miller JB (1999) Modulation of the baboon (*Papio anubis*) uterine endometrium by chorionic gonadotropin during the period of uterine receptivity. *Proc Natl Acad Sci USA* 96,2543–2548.
- Giudice LC (1999) Potential biochemical markers of uterine receptivity. *Hum Reprod* 14 (Suppl. 2),3–16.
- Godkin JD and Doré JJ (1998) Transforming growth factor beta and the endometrium. *Rev Reprod* 3,1–6.
- Han SW, Lei ZM and Rao CV (1999) Treatment of human endometrial stromal cells with chorionic gonadotropin promotes their morphological and functional differentiation into decidua. *Mol Cell Endocrinol* 147,7–16.
- Han VK and Carter AM (2000) Spatial and temporal patterns of expression of messenger RNA for insulin-like growth factors and their binding proteins in the placenta of man and laboratory animals. *Placenta* 21,289–305.
- Irwin JC, Suen LF, Martina NA, Mark SP and Giudice L (1999) Role of the IGF system in trophoblast invasion and pre-eclampsia. *Hum Reprod* 14 (Suppl. 2),90–96.
- Jensen JD and Odell WD (1988) Identification of LH/hCG receptors in rabbit uterus. *Proc Soc Exp Biol Med* 189,28–30.
- Juriscova A, Antenos M, Kapasi K, Meriano J and Casper RF (1999) Variability in the expression of trophoctodermal markers beta-human chorionic gonadotropin, human leukocyte antigen-G and pregnancy specific beta-1 glycoprotein by the human blastocyst. *Hum Reprod* 14,1852–1858.
- Kauma S, Matt D, Strom S, Eierman D and Turner T (1990) Interleukin-1 beta, human leukocyte antigen HLA-DR alpha, and transforming growth factor-beta expression in endometrium, placenta, and placental membranes. *Am J Obstet Gynecol* 163,1430–1437.
- Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R and Arici A (2003) Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. *J Immunol* 171,2305–2313.
- Khan NA, Khan A, Savelkoul HF and Benner R (2001) Inhibition of diabetes in NOD mice by human pregnancy factor. *Hum Immunol* 62,1315–1323.
- Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H and Köhler G (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. *Nature* 368, 339–342.
- Laird SM, Li TC and Bolton AE (1993) The production of placental protein 14 and interleukin 6 by human endometrial cells in culture. *Hum Reprod* 8,793–798.
- Laird SM, Tuckerman E, Li TC and Bolton AE (1994) Stimulation of human endometrial epithelial cell interleukin 6 production by interleukin 1 and placental protein 14. *Hum Reprod* 9,1339–1343.
- Laird SM, Tuckerman EM, Dalton CF, Dunphy BC, Li TC and Zhang X (1997) The production of leukaemia inhibitory factor by human endometrium: presence in uterine flushings and production by cells in culture. *Hum Reprod* 12,569–574.
- Ledee-Bataille N, Lapree-Delage G, Taupin JL, Dubanchet S, Frydman R and Chaouat G (2002) Concentration of leukaemia inhibitory factor (LIF) in uterine flushing fluid is highly predictive of embryo implantation. *Hum Reprod* 17,213–218.
- Li Y, Matsuzaki N, Masuhiro K, Kameda T, Taniguchi T, Saji F, Yone K and Tanizawa O (1992) Trophoblast-derived tumor necrosis factor-alpha induces release of human chorionic gonadotropin using interleukin-6 (IL-6) and IL-6-receptor-dependent system in the normal human trophoblasts. *J Clin Endocrinol Metab* 74,184–191.
- Licht P, Russu V and Wildt L (2001) On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation. *Semin Reprod Med* 19,37–47.
- Licht P, von Wolff M, Berkholz A and Wildt L (2003) Evidence for cycle-dependent expression of full-length human chorionic gonadotropin/luteinizing hormone receptor mRNA in human endometrium and decidua. *Fertil Steril* 79 (Suppl. 1),718–723.
- Lopata A, Oliva K, Stanton PG and Robertson DM (1997) Analysis of chorionic gonadotropin secreted by cultured human blastocysts. *Mol Hum Reprod* 3,517–521.
- Martens H, Malgrange B, Robert F et al. (1996) Cytokine production by human thymic epithelial cells: control by the immune recognition of the neurohypophysial self-antigen. *Regul Pept* 67,39–45.
- Masuhiro K, Matsuzaki N, Nishino E, Taniguchi T, Kameda T, Li Y, Saji F and Tanizawa O (1991) Trophoblast-derived interleukin-1 (IL-1) stimulates the release of human chorionic gonadotropin by activating IL-6 and IL-6-receptor system in first trimester human trophoblasts. *J Clin Endocrinol Metab* 72,594–601.
- Merali FS, Arck PC, Beaman K and Clark DA (1996) Transforming growth factor-beta 2-related-decidual suppressor factor is not related to TJ6 protein. *Am J Reprod Immunol* 35,342–347.
- Nakayama T, Fujiwara H, Maeda M, Inoue T, Yoshioka S, Mori T and Fujii S (2002) Human peripheral blood mononuclear cells (PBMC) in early pregnancy promote embryo invasion in vitro: HCG enhances the effects of PBMC. *Hum Reprod* 17,207–212.
- Nayak NR and Giudice LC (2003) Comparative biology of the IGF system in endometrium, decidua, and placenta, and clinical implications for foetal growth and implantation disorders. *Placenta* 24,281–296.
- Nishino E, Matsuzaki N, Masuhiro K, Kameda T, Taniguchi T, Takagi T, Saji F and Tanizawa O (1990) Trophoblast-derived interleukin-6 (IL-6) regulates human chorionic gonadotropin release through IL-6 receptor on human trophoblasts. *J Clin Endocrinol Metab* 71,436–441.
- Noyes RW, Hertig AI and Rock I (1950) Dating the endometrial biopsy. *Fertil Steril* 1,3–25.
- Rao CV (2001) An overview of the past, present, and future of nongonadal LH/hCG actions in reproductive biology and medicine. *Semin Reprod Med* 19,7–17.

- Rao CV (2002) LH receptors: follicle and endometrium. *J Gynecol Obstet Biol Reprod* 31,1S7–1S11.
- Reshef E, Lei ZM, Rao CV, Pridham DD, Chegini N and Luborsky JL (1990) The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. *J Clin Endocrinol Metab* 70,421–430.
- Robert F, Geenen V, Schoenen J, Burgeon E, De Groote D, Defresne MP, Legros JJ and Franchimont P (1991) Colocalization of immunoreactive oxytocin, vasopressin and interleukin-1 in human thymic epithelial neuroendocrine cells. *Brain Behav Immun* 5,102–115.
- Robertson SA, Mayrhofer G and Seamark RF (1992) Uterine epithelial cells synthesize granulocyte-macrophage colony-stimulating factor and interleukin-6 in pregnant and nonpregnant mice. *Biol Reprod* 46,1069–1079.
- Rutanen EM (1998) Insulin-like growth factors in endometrial function. *Gynecol Endocrinol* 12,399–406.
- Salamonsen LA, Dimitriadis E and Robb L (2000) Cytokines in implantation. *Semin Reprod Med* 18,299–310.
- Sawai K, Matsuzaki N, Kameda T et al. (1995) Leukemia inhibitory factor produced at the fetomaternal interface stimulates chorionic gonadotropin production: its possible implication during pregnancy, including implantation period. *J Clin Endocrinol Metab* 80,1449–1456.
- Sharkey AM, Dellow K, Blayney M, Macnamee M, Charnock-Jones S and Smith SK (1995) Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. *Biol Reprod* 53,974–981.
- Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Köntgen F and Abbondanzo SJ (1992) Blastocyst implantation depends on maternal expression of leukemia inhibitory factor [see comments]. *Nature* 359,76–79.
- Stewart EA (2001) Gonadotropins and the uterus: is there a gonad-independent pathway? *J Soc Gynecol Investig* 8,319–326.
- Stewart EA, Sahakian M, Rhoades A, Van Voorhis BJ and Nowak RA (1999) Messenger ribonucleic acid for the gonadal luteinizing hormone/human chorionic gonadotropin receptor is not present in human endometrium. *Fertil Steril* 71,368–372.
- Tabibzadeh S, Kong QF, Babaknia A and May LT (1995) Progressive rise in the expression of interleukin-6 in human endometrium during menstrual cycle is initiated during the implantation window. *Hum Reprod* 10, 2793–2799.
- Tabibzadeh S, Lessey B and Satyaswaroop PG (1998) Temporal and site-specific expression of transforming growth factor-beta4 in human endometrium. *Mol Hum Reprod* 4,595–602.
- Uzumcu M, Coskun S, Jaroudi K and Hollanders JM (1998) Effect of human chorionic gonadotropin on cytokine production from human endometrial cells in vitro. *Am J Reprod Immunol* 40,83–88.
- Vandermolen DT and Gu Y (1996) Human endometrial interleukin-6 (IL-6): in vivo messenger ribonucleic acid expression, in vitro protein production, and stimulation thereof by IL-1 beta. *Fertil Steril* 66,741–747.
- Zhang M, Shi H, Segaloff DL, Van Voorhis BJ and Zheng M (2001) Expression and localization of luteinizing hormone receptor in the female mouse reproductive tract. *Biol Reprod* 64,179–187.
- Zhou XL, Lei ZM and Rao CV (1999) Treatment of human endometrial gland epithelial cells with chorionic gonadotropin/luteinizing hormone increases the expression of the cyclooxygenase-2 gene. *J Clin Endocrinol Metab* 84,3364–3377.
- Ziecik AJ, Stanchev PD and Tilton JE (1986) Evidence for the presence of luteinizing hormone/human chorionic gonadotropin-binding sites in the porcine uterus. *Endocrinol* 119,1159–1163.

*Submitted on March 22, 2004; resubmitted on June 4, 2004; accepted on July 13, 2004*